SWTX

SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma

SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children's Tumor Foundation NF Conference

SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma

SpringWorks Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

SpringWorks Therapeutics to Present at the Cowen 2nd Annual Oncology Innovation Summit

SpringWorks Therapeutics Appoints Dr. Mike Burgess as Head of Research and Development

SpringWorks Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights